The Tuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis (MTB) that, despite some reduction in its incidence, prevalence and mortality in the last 10 years, is still far from being eradicated. On the one hand, we see the effectiveness of global plans reducing the number of individuals infected with susceptible strains to treatment and the other side the rise of multi-drug-resistant mycobacteria, which presents inversely proportional numbers to the success of government actions. One should keep in mind that the current treatment, although older, is highly effective against susceptible MTB infection. However, there are no many options to those individuals with multi-drug-resistant infections (MDR), extensively drug-resistant (XDR) or even totally drug-resistant (TDR). Focused on the development of new molecules by different strategies, and in collaboration with other research groups, we aimed at developing molecules that can tackle dug resistant strains. Within the Young Researcher Award FAPESP (2013 / 14957-5), a group of inorganic molecules have shown great potential against different resistant strains as well as high selective toxicity. Therefore, this research project proposes a deeper knowledge of the pharmacodynamic of 2-mercaptopyridine N-oxide sodium salt [Na mpo] and its complex with iron [Fe (mpo) 3]. We will confirm the Minimum Inhibitory Concentration (MIC) and determine the Minimum Bactericidal Concentration (MBC) and the Time-kill kinetics of these compounds against different clinical strains of MTB that have, or not, resistance to drugs currently used in the treatment of TB.
News published in Agência FAPESP Newsletter about the scholarship: